Philippé J, Offner F, Declerck P J, Leroux-Roels G, Vogelaers D, Baele G, Collen D
Department of Clinical Chemistry, University Hospital of Gent, Belgium.
Thromb Haemost. 1991 Mar 4;65(3):291-5.
Sepsis is often associated with hemostatic dysfunction. This study aimed to relate changes in fibrinolysis and coagulation parameters to sepsis and sepsis outcome. Urokinase-type plasminogen activator (u-PA) antigen, tissue-type plasminogen activator (t-PA) antigen and activity, plasminogen activator inhibitor (PAI) type 1 antigen, PAI activity, antithrombin (AT) III activity, and protein C activity were measured in 24 patients suffering from sepsis or septic shock and the results were compared with those observed in 30 non-sepsis patients with severe infectious disease. The u-PA level was markedly increased in plasma of sepsis patients as compared to non-sepsis patients (11.5 +/- 9.4 versus 1.6 +/- 1.5 ng/ml, p less than 0.0001). PAI-1 antigen and t-PA activity showed a significant increase in sepsis patients (320 +/- 390 ng/ml versus 120 +/- 200 ng/ml, and 3.0 +/- 3.6 IU/ml versus 1.0 +/- 0.7 IU/ml, respectively, p less than 0.01). AT III was decreased in sepsis patients (58 +/- 28% in sepsis versus 79 +/- 26% in severe infectious disease, p less than 0.01) as was protein C (30 +/- 18% versus 58 +/- 27%, p less than 0.001). No significant difference was found for t-PA antigen nor for PAI activity. Nonsurvivors of sepsis were distinguished mainly by a high u-PA antigen level and increased t-PA activity. It is concluded that plasma u-PA antigen showed the strongest significant difference, among the parameters evaluated, between sepsis and severe infection. u-PA antigen may be of prognostic value in patients admitted to the medical intensive care unit for severe infectious disease.
脓毒症常与止血功能障碍相关。本研究旨在探讨纤溶和凝血参数变化与脓毒症及脓毒症预后的关系。检测了24例脓毒症或脓毒性休克患者的尿激酶型纤溶酶原激活物(u-PA)抗原、组织型纤溶酶原激活物(t-PA)抗原及活性、纤溶酶原激活物抑制剂(PAI)-1抗原、PAI活性、抗凝血酶(AT)III活性和蛋白C活性,并将结果与30例患有严重感染性疾病的非脓毒症患者进行比较。与非脓毒症患者相比,脓毒症患者血浆中的u-PA水平显著升高(11.5±9.4对1.6±1.5 ng/ml,p<0.0001)。脓毒症患者的PAI-1抗原和t-PA活性显著增加(分别为320±390 ng/ml对120±200 ng/ml,以及3.0±3.6 IU/ml对1.0±0.7 IU/ml,p<0.01)。脓毒症患者的AT III降低(脓毒症患者为58±28%,严重感染性疾病患者为79±26%,p<0.01),蛋白C也降低(30±18%对58±27%,p<0.001)。t-PA抗原和PAI活性未发现显著差异。脓毒症非存活者的主要特征是u-PA抗原水平高和t-PA活性增加。结论是,在所评估的参数中,血浆u-PA抗原在脓毒症和严重感染之间显示出最显著的差异。u-PA抗原可能对因严重感染性疾病入住医疗重症监护病房的患者具有预后价值。